Literature DB >> 12768253

SQUID biosusceptometry in the measurement of hepatic iron.

Sujit Sheth1.   

Abstract

Individuals with primary or secondary abnormalities of iron metabolism, such as hereditary hemochromatosis and transfusional iron loading, may develop potentially lethal systemic iron overload. Over time, this excess iron is progressively deposited in the liver, heart, pancreas, and other organs, resulting in cirrhosis, heart disease, diabetes and other disorders. Unless treated, death usually results from cardiac failure. The amount of iron in the liver is the best indicator of the amount of iron in the whole body. At present, the only sure way to measure the amount of iron in the liver is to remove a sample of the liver by biopsy. Iron stored in the liver can be magnetized to a small degree when placed in a magnetic field. The amount of magnetization is measured by our instrument, called a superconducting quantum interference device (SQUID) susceptometer. In patients with iron overload, our previous studies have shown that magnetic measurements of liver iron in patients with iron overload are quantitatively equivalent to biochemical determinations on tissue obtained by biopsy. The safety, ease, rapidity, and comfort of magnetic measurements make frequent, serial studies technically feasible and practically acceptable to patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12768253     DOI: 10.1007/s00247-003-0877-x

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  11 in total

Review 1.  Genetic disorders affecting proteins of iron metabolism: clinical implications.

Authors:  S Sheth; G M Brittenham
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

Review 2.  Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease.

Authors:  G M Brittenham; S Sheth; C J Allen; D E Farrell
Journal:  Semin Hematol       Date:  2001-01       Impact factor: 3.851

3.  Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases.

Authors:  P Nielsen; R Engelhardt; M Duerken; G E Janka; R Fischer
Journal:  Transfus Sci       Date:  2000-12

Review 4.  Noninvasive methods for the early detection of hereditary hemochromatosis.

Authors:  G M Brittenham
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry.

Authors:  R Fischer; C D Tiemann; R Engelhardt; P Nielsen; M Dürken; E E Gabbe; G E Janka
Journal:  Am J Hematol       Date:  1999-04       Impact factor: 10.047

Review 6.  Iron-chelating therapy and the treatment of thalassemia.

Authors:  N F Olivieri; G M Brittenham
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

7.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major.

Authors:  N F Olivieri; G M Brittenham; D Matsui; M Berkovitch; L M Blendis; R G Cameron; R A McClelland; P P Liu; D M Templeton; G Koren
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

8.  Magnetic-susceptibility measurement of human iron stores.

Authors:  G M Brittenham; D E Farrell; J W Harris; E S Feldman; E H Danish; W A Muir; J H Tripp; E M Bellon
Journal:  N Engl J Med       Date:  1982-12-30       Impact factor: 91.245

9.  Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone.

Authors:  P Nielsen; R Fischer; R Engelhardt; P Tondüry; E E Gabbe; G E Janka
Journal:  Br J Haematol       Date:  1995-12       Impact factor: 6.998

10.  Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major.

Authors:  G M Brittenham; A R Cohen; C E McLaren; M B Martin; P M Griffith; A W Nienhuis; N S Young; C J Allen; D E Farrell; J W Harris
Journal:  Am J Hematol       Date:  1993-01       Impact factor: 10.047

View more
  6 in total

Review 1.  Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

Authors:  Ellis J Neufeld
Journal:  Blood       Date:  2006-05-01       Impact factor: 22.113

2.  Magnetic susceptibility as a B0 field strength independent MRI biomarker of liver iron overload.

Authors:  Diego Hernando; Rachel J Cook; Carol Diamond; Scott B Reeder
Journal:  Magn Reson Med       Date:  2013-06-25       Impact factor: 4.668

3.  Trends in transfusion burden among long-term survivors of childhood hematological malignancies.

Authors:  Kerri Nottage; James G Gurney; Matthew Smeltzer; Maria Castellanos; Melissa M Hudson; Jane S Hankins
Journal:  Leuk Lymphoma       Date:  2012-12-22

Review 4.  Treating iron overload in patients with non-transfusion-dependent thalassemia.

Authors:  Ali T Taher; Vip Viprakasit; Khaled M Musallam; M Domenica Cappellini
Journal:  Am J Hematol       Date:  2013-03-08       Impact factor: 10.047

5.  A Room Temperature Ultrasensitive Magnetoelectric Susceptometer for Quantitative Tissue Iron Detection.

Authors:  Hao Xi; Xiaoshi Qian; Meng-Chien Lu; Lei Mei; Sebastian Rupprecht; Qing X Yang; Q M Zhang
Journal:  Sci Rep       Date:  2016-07-28       Impact factor: 4.379

Review 6.  Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives.

Authors:  Karim Bayanzay; Lama Alzoebie
Journal:  J Blood Med       Date:  2016-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.